Imaging-Based Biomarkers Predict Programmed Death-Ligand 1 and Survival Outcomes in Advanced NSCLC Treated With Nivolumab and Pembrolizumab: A Multi-Institutional Study
Open Access
- 18 November 2023
- journal article
- research article
- Published by Elsevier in JTO Clinical and Research Reports
- Vol. 4 (12) , 100602
Abstract
No abstract availableKeywords
Funding Information
- Santé
This publication has 31 references indexed in Scilit:
- A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort studyThe Lancet Oncology, 2018
- Benchmarking relief-based feature selection methods for bioinformatics data miningJournal of Biomedical Informatics, 2018
- Relief-based feature selection: Introduction and reviewJournal of Biomedical Informatics, 2018
- Computational Radiomics System to Decode the Radiographic PhenotypeCancer Research, 2017
- PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?Journal for ImmunoTherapy of Cancer, 2016
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2016
- Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancerExpert Review of Anticancer Therapy, 2015
- Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approachNature Communications, 2014
- The Evolution of Boosting AlgorithmsMethods of Information in Medicine, 2014
- The gradient boosting algorithm and random boosting for genome-assisted evaluation in large data setsJournal of Dairy Science, 2013